Article Text
Therapeutics
Randomised controlled trial
Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors
Statistics from Altmetric.com
Footnotes
-
Competing interests None.